Cookie Policy: This site uses cookies to improve your experience. You can find out more about our use of cookies in our Privacy Policy. By continuing to browse this site you agree to our use of cookies.
Bertin Bioreagent
anti-TAF6, mAb (2G7)
As low as
664
CHF
CHF 664.00
In stock
Only %1 left
BRT-G01086-R100100 µlCHF 664.00

Product Details | |
---|---|
Synonyms | Transcription Initiation Factor TFIID Subunit 6; TATA-Box Binding Protein-Associated Factor 6; TAFII70; TAFII80; RNA Polymerase II TBP-associated Factor Subunit E |
Product Type | Monoclonal Antibody |
Properties | |
Clone | 2G7 |
Isotype | Mouse IgG1κ |
Source/Host | Mouse |
Immunogen/Antigen | Synthetic peptide. |
Application | ELISA, Western Blot (natural and recombinant proteines), Immunocytofluorescence. Recommended dilutions: 1/500-1/1000. |
Specificity | Recognizes human and mouse TAF6. |
Formulation | Liquid. Does not contain any preservative. |
Other Product Data |
Click here for Original Manufacturer Product Datasheet |
Declaration | Manufactured by Bertin Bioreagent |
Shipping and Handling | |
Shipping | BLUE ICE |
Long Term Storage | -20°C |
Handling Advice | Avoid freeze/thaw cycles. |
Use/Stability | Stable for at least 3 years after receipt when stored at -20°C. |
Documents | |
Product Specification Sheet | |
Datasheet |
![]() |
Description
TAF6 is a core subunit of the TFIID complex, which is essential for RNA polymerase II-dependent transcription initiation. It plays a significant role in gene expression regulation by participating in the formation and stability of the TFIID complex. TAF6 is an important subunit of the TFIID complex, a multi-protein complex involved in the recognition of core promoter elements (such as the TATA box) and the recruitment of RNA polymerase II to initiate transcription. TAF6 works closely with other TAFs (like TAF1, TAF4, TAF5, and TAF12) to stabilize the complex and help in the assembly of the transcription machinery. TAF6 may contribute to chromatin remodeling, facilitating accessibility of DNA to the transcription machinery. Disruptions in TAF6 function may contribute to tumorigenesis and cancer progression, especially through the dysregulation of genes involved in cell cycle control and apoptosis. Mutations or altered expression of TAF6 could potentially contribute to neurological diseases that involve defects in gene expression regulation.